The 3 best ASX travel stocks according to Stocks Down Under
Marc Kennis, August 11, 2023
The trend of “revenge travel” isn’t slowing down, despite predictions of a downturn. Quite the contrary, travel now forms a significant portion of household budgets, showing up prominently in company share prices and market performance.
Our own Stuart Roberts says travel expenditures continue to constitute a crucial part of household budgets. He emphasizes the ongoing prosperity in the travel sector, using Airbnb’s latest figures as evidence. This data indicates an 11% YoY growth, demonstrating the industry’s resilience.
What are the Best ASX Travel stocks to invest in right now?
Check our buy/sell tips on the top ASX Travel stocks
As for the future of travel, Stuart looks toward potential stars like Flight Center (ASX:FLT) and SiteMinder (ASX:SDR), who are making waves in the industry. Additionally, he introduces Jayride (ASX:JAY) – a global aggregator for ride services linking airports with hotels, which Stuart perceives as a potential game-changer.
In spite of the pandemic’s challenges, he suggests numerous companies may still benefit from the ‘revenge travel’ trend. Stuart urges us to overlook negative conjecture around the financial health of the travel industry, alluding to the ongoing success seen in various companies’ share prices as counter evidence.
CHECK OUT STUART’S INTERVIEW ON AUSBIZ BELOW!
Stuart Roberts talking about the best ASX travel stocks on AusBiz
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…
Here are 5 key ASX Listing Rules that investors need to know about!
All companies listed on the ASX need to know about the ASX Listing Rules. The reason is obvious: Because there’s…
Here are 3 ASX stocks fighting diabetes and the opportunity ahead of them
There aren’t many ASX stocks fighting diabetes, but the few that are have a big market opportunity ahead of them. And…